PDL BioPharma, Inc. (NASDAQ:PDLI) went up by 3.79% from its latest closing price when compared to the 1-year high value of $3.47 and move down -15.28%, while PDLI stocks collected +7.31% of gains with the last five trading sessions. Press Release reported on 05/21/20 that PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
PDL BioPharma, Inc. (NASDAQ:PDLI) Worth an Investment?
PDL BioPharma, Inc. (NASDAQ: PDLI) The 36 Months beta value for PDLI stocks is at 0.92, while 0 of the analysts out of 1 who provided ratings for PDL BioPharma, Inc. stocks as a “buy” while 0 as overweight, 1 rated it as hold and 0 as sell. The average price we get from analysts is $2.49 which is -$3.01 below current price. PDLI currently has a short float of 10.10% and public float of 110.16M with average trading volume of 1.18M shares.
PDLI Market Performance
PDLI stocks went up by 7.31% for the week, with the monthly drop of -6.81% and a quarterly performance of 18.11%, while its annual performance rate touched 12.96%. The simple moving average for the period of the last 20 days is 3.48% for PDLI stocks with the simple moving average of 12.56% for the last 200 days.
Analysts’ Opinion on PDL BioPharma, Inc. (NASDAQ:PDLI)
Many brokerage firms have already submitted their reports for PDLI stocks, with Piper Jaffray repeating the rating for PDLI shares by setting it to “Overweight”. The predicted price for PDLI socks in the upcoming period according to Piper Jaffray is $42 based on the research report published on December 22, 2016.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see PDLI stock at the price of $4, previously predicting the value of $5. The rating they have provided for PDLI stocks is “Sector Perform” according to the report published on February 23, 2016.
RBC Capital Mkts gave “Sector Perform” rating to PDLI stocks, setting the target price at $5 in the report published on February 2, 2016.
PDLI Stocks -2.22% Far from 50 Day Moving Average
After a stumble in the market that brought PDLI to its low price for the period of the last 52 weeks, PDL BioPharma, Inc. was unable to take a rebound, for now settling with -13.26% of loss for the given period.
The stock volatility was left at 4.46%, however, within the period of a single month, the volatility rate increased by 3.52%, while the shares sank at the distance of -4.14% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -13.01% lower at the present time.
In the course of the last 5 trading sessions, PDLI went up by +7.31%, which changed the moving average for the period of 200 days to the total of +41.31% of gains for the stock in comparison to the 20-day moving average settled at $2.90. In addition, PDL BioPharma, Inc. saw 11.74% in overturn over the period of a single year with a tendency to cut further gains.
PDLI Stock Fundamentals
The current profitability levels are settled at -121.55 for the present operating margin and -9.44 for gross margin. The net margin for PDL BioPharma, Inc. stands at -128.59. Total capital return value is set at -9.01, while invested capital returns managed to touch -9.54.
Based on PDL BioPharma, Inc. (PDLI), the company’s capital structure generated 4.88 points for debt to equity in total, while total debt to capital is set at the value of 4.65. Total debt to assets is settled at the value of 4.04 with long-term debt to equity ratio rests at -5.84 and long-term debt to capital is 4.72.
The value for Enterprise to Sales is 4.03 with debt to enterprise value settled at 0.13. The receivables turnover for PDL BioPharma, Inc. is 0.70 with the total asset turnover at the value of 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.